REG - Cellbxhealth PLC - Update to Admission of Fundraising Shares

CellbxhealthAnnouncement

25/11/2025 17:45

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251125:nRSY9815Ia&default-theme=true

RNS Number : 9815I  Cellbxhealth PLC  25 November 2025

CELLBXHEALTH plc

("CELLBXHEALTH", the "Company" or the "Group")

Update to Admission of Fundraising Shares

CELLBXHEALTH plc (AIM: CLBX), a leader in circulating tumour cell (CTC)
intelligence announces, following the conclusion of the oversubscribed
Placing, the following update with regards Admission of the Fundraising
Shares.

Subject to the passing of the Resolutions, First Admission will be in respect
of 9,090,000 First Tranche Fundraising Shares and is expected to occur at 8.00
a.m. on or around 16 December 2025.   Second Admission will be in respect of
up to 770,910,000 Second Tranche Placing Shares, the Subscription Shares and
the Retail Offer Shares and is expected to occur at 8.00 a.m. on 18 December
2025 (or, in each case, such later time and/or date as Cavendish and the
Company and Cavendish may agree, not (being no later than 8.00 a.m. on 16
January 2026).

Capitalised terms used but not defined in this announcement have the meanings
given to them in the Launch Announcement, unless context provides otherwise.

For further information:

 

 CelLBxHealth plc                                               +44 (0) 1483 343434
 Peter Collins, Chief Executive Officer                          investor@CelLBxHealth.com

 Cavendish (NOMAD and Broker)

 Geoff Nash / Isaac Hooper / Hamza Munshi (Corporate Finance)   +44 (0) 20 7220 0500

 Sunila de Silva (Corporate Broking)

 Nigel Birks (Life Science Specialist Sales)

 FTI Consulting

 Simon Conway, Ciara Martin, Sam Purewal                        +44 (0) 203 727 1000

This Announcement is for information purposes only and does not constitute an
offer to sell or issue or the solicitation of an offer to buy, acquire or
subscribe for shares in the capital of the Company in the United States,
Australia, Canada, Japan or the Republic of South Africa or any other
jurisdiction where such offer or solicitation may be restricted, unlawful or
unauthorised. Any failure to comply with these restrictions may constitute a
violation of the securities laws of such jurisdictions. Subject to certain
exemptions, the securities referred to herein may not be offered or sold in
Canada, Australia, Japan or the Republic of South Africa or to, or for the
account or benefit of any national resident or citizen of Canada, Australia,
Japan or the Republic of South Africa. The Ordinary Shares have not been and
will not be registered under the Securities Act of 1933, as amended (the
"Securities Act") or the securities laws of any other jurisdiction of the
United States, and may not be offered, sold or transferred, directly or
indirectly, in the United States absent registration under the Securities Act
or an available exemption from, or in a transaction not subject to, the
registration requirements of the Securities Act and the securities laws of any
other jurisdiction of the United States. No public offering of the shares
referred to in this Announcement is being made in the United States, United
Kingdom, Australia, Canada, Japan, the Republic of South Africa or elsewhere.

About CelLBxHealth plc

CelLBxHealth plc is a CTC intelligence company specialising in innovative
circulating tumour cell (CTC) solutions for use in research, drug development
and clinical oncology. Its patent-protected Parsortix® platform harvests CTCs
from blood and can be seamlessly integrated with existing laboratory
instruments for comprehensive downstream analysis - including whole-cell
imaging, proteomic profiling and full genomic workflows.

Commercial activities centre on (1) Product Sales:  Accelerating Parsortix
platform adoption and consumable sales through CROs* and clinical lab
partnerships. (2) Lab Developed Tests (LDTs): Strategic partnerships combined
with a focused in-house development programme. (3) Laboratory services:
Clinical trial support and assay development.

The product portfolio comprises the Parsortix® platform with associated
consumables and assays. Laboratory services are delivered from CelLBxHealth's
GCLP certified UK laboratory, providing bespoke clinical-trial support and
assay development.

For more information, visit https://cellbxhealth.com/.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  IOEFZMZMNKGGKZM



            Copyright 2019 Regulatory News Service, all rights reserved